Minerva Neurosciences (NERV) Change in Cash (2013 - 2026)

Minerva Neurosciences has reported Change in Cash for 14 years, with the latest figure at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 1119.12% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (up 187.69% YoY), and the FY2025 full-year result was $60.9 million, up 411.7% from the prior year.
• Change in Cash for Q1 2026 stood at -$49.6 million, down from $70.0 million in the prior quarter.
• The five-year high for Change in Cash was $70.0 million in Q4 2025, with the low at -$49.6 million in Q1 2026.
• Historically, Change in Cash has averaged -$1.7 million across 5 years, with a median of -$4.4 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Cash slumped 5180.68% — and 2025, when it soared 1455.1%.
• Minerva Neurosciences' Change in Cash stood at -$4.1 million in 2022, then tumbled by 45.2% to -$6.0 million in 2023, then grew by 13.76% to -$5.2 million in 2024, then soared by 1455.1% to $70.0 million in 2025, then plunged by 170.9% to -$49.6 million in 2026.
• The last three Change in Cash figures came in at -$49.6 million (Q1 2026), $70.0 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.